Skip to Main Content
Mental Health & Behavioral Research

Imaging SV2A in mood disorders

What is the purpose of this trial?

The goal of the study is to determine whether there are alterations in synaptic vesicle glycoprotein 2A (SV2A), a protein expressed ubiquitously in synaptic vesicles, in depression and anxiety and whether ketamine, an N-Methyl-D-aspartate (NMDA) antagonist, normalizes SV2A density at time of its greatest anti-depressant response. We will conduct an examination of SV2A and associated consequences using neuroreceptor imaging and behavioral techniques.

  • Trial with
    Yale University School of Medicine and National Institute of Mental Health (NIMH)
  • Ages
    18 years - 70 years
  • Gender
    Both

Contact Information

For more information about this study, including how to volunteer, contact Sarah Boster

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

  • Last Updated
    03/26/2024
  • Study HIC
    #1511016789